NO20054631D0 - Antistoff mot tumorspesifikt antigen som mal - Google Patents
Antistoff mot tumorspesifikt antigen som malInfo
- Publication number
- NO20054631D0 NO20054631D0 NO20054631A NO20054631A NO20054631D0 NO 20054631 D0 NO20054631 D0 NO 20054631D0 NO 20054631 A NO20054631 A NO 20054631A NO 20054631 A NO20054631 A NO 20054631A NO 20054631 D0 NO20054631 D0 NO 20054631D0
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- template
- antibody against
- specific antigen
- tumor specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003063648 | 2003-03-10 | ||
| PCT/JP2004/003048 WO2004081050A1 (ja) | 2003-03-10 | 2004-03-09 | 癌特異的抗原を標的とした抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054631D0 true NO20054631D0 (no) | 2005-10-07 |
| NO20054631L NO20054631L (no) | 2005-12-09 |
Family
ID=32984436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054631A NO20054631L (no) | 2003-03-10 | 2005-10-07 | Antistoff mot tumorspesifikt antigen som mal |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7855056B2 (no) |
| EP (1) | EP1602669B1 (no) |
| JP (1) | JP4462964B2 (no) |
| KR (1) | KR20050116374A (no) |
| CN (2) | CN1784426A (no) |
| AT (1) | ATE434044T1 (no) |
| AU (1) | AU2004220182B2 (no) |
| BR (1) | BRPI0408238A (no) |
| CA (1) | CA2518787A1 (no) |
| DE (1) | DE602004021567D1 (no) |
| DK (1) | DK1602669T3 (no) |
| ES (1) | ES2327408T3 (no) |
| HK (1) | HK1078593A1 (no) |
| MX (1) | MXPA05009715A (no) |
| NO (1) | NO20054631L (no) |
| NZ (1) | NZ542220A (no) |
| RU (1) | RU2345090C2 (no) |
| TW (1) | TW200508249A (no) |
| WO (1) | WO2004081050A1 (no) |
| ZA (1) | ZA200507298B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200510282B (en) * | 2003-07-02 | 2007-03-28 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| US8426151B2 (en) * | 2010-02-10 | 2013-04-23 | Companion Diagnostics Inc. | Systems and methods for the detection of biomarkers |
| CN103168377A (zh) | 2010-11-05 | 2013-06-19 | 株式会社Lg化学 | 具有改善的安全性的二次电池 |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US20140224373A1 (en) * | 2013-02-12 | 2014-08-14 | MPS Enterprises, Inc. | Lay-flat hose for oilfield hydraulic fracturing operations |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| KR102665199B1 (ko) * | 2018-11-15 | 2024-05-14 | 삼성디스플레이 주식회사 | 레이저 장치 및 이를 이용한 기판 식각 방법 |
| WO2021072139A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| US5728821A (en) * | 1994-08-04 | 1998-03-17 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| CA2331998A1 (en) | 1998-05-08 | 1999-11-18 | Toyama Chemical Co., Ltd. | Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same |
| CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| WO2002016603A2 (en) * | 2000-08-21 | 2002-02-28 | Millennium Pharmaceuticals, Inc. | 23228, a novel human tetraspanin family member and uses thereof |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20070042360A1 (en) * | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| AU2002330039A1 (en) * | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| WO2003088808A2 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
| ZA200510282B (en) * | 2003-07-02 | 2007-03-28 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
-
2004
- 2004-03-08 JP JP2004063301A patent/JP4462964B2/ja not_active Expired - Fee Related
- 2004-03-09 KR KR1020057016909A patent/KR20050116374A/ko not_active Application Discontinuation
- 2004-03-09 DE DE602004021567T patent/DE602004021567D1/de not_active Expired - Lifetime
- 2004-03-09 RU RU2005128277/13A patent/RU2345090C2/ru not_active IP Right Cessation
- 2004-03-09 EP EP04718767A patent/EP1602669B1/en not_active Expired - Lifetime
- 2004-03-09 CA CA002518787A patent/CA2518787A1/en not_active Abandoned
- 2004-03-09 WO PCT/JP2004/003048 patent/WO2004081050A1/ja active Application Filing
- 2004-03-09 TW TW093106168A patent/TW200508249A/zh unknown
- 2004-03-09 AT AT04718767T patent/ATE434044T1/de not_active IP Right Cessation
- 2004-03-09 ES ES04718767T patent/ES2327408T3/es not_active Expired - Lifetime
- 2004-03-09 NZ NZ542220A patent/NZ542220A/en unknown
- 2004-03-09 BR BRPI0408238-9A patent/BRPI0408238A/pt not_active IP Right Cessation
- 2004-03-09 CN CNA2004800126663A patent/CN1784426A/zh active Pending
- 2004-03-09 AU AU2004220182A patent/AU2004220182B2/en not_active Ceased
- 2004-03-09 DK DK04718767T patent/DK1602669T3/da active
- 2004-03-09 MX MXPA05009715A patent/MXPA05009715A/es unknown
- 2004-03-09 US US10/548,688 patent/US7855056B2/en not_active Expired - Fee Related
- 2004-03-09 CN CN2010101090755A patent/CN102151334A/zh active Pending
-
2005
- 2005-09-09 US US11/223,812 patent/US7361340B2/en not_active Expired - Fee Related
- 2005-09-09 ZA ZA200507298A patent/ZA200507298B/en unknown
- 2005-10-07 NO NO20054631A patent/NO20054631L/no not_active Application Discontinuation
-
2006
- 2006-01-09 HK HK06100346.5A patent/HK1078593A1/xx not_active IP Right Cessation
- 2006-01-31 US US11/345,651 patent/US20070025996A1/en not_active Abandoned
-
2007
- 2007-10-15 US US11/872,479 patent/US7741447B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005128277A (ru) | 2006-06-10 |
| ZA200507298B (en) | 2006-06-28 |
| TW200508249A (en) | 2005-03-01 |
| JP2004290187A (ja) | 2004-10-21 |
| HK1078593A1 (en) | 2006-03-17 |
| NZ542220A (en) | 2008-04-30 |
| US20070025996A1 (en) | 2007-02-01 |
| DK1602669T3 (da) | 2009-09-14 |
| US20070166312A1 (en) | 2007-07-19 |
| EP1602669B1 (en) | 2009-06-17 |
| US7855056B2 (en) | 2010-12-21 |
| NO20054631L (no) | 2005-12-09 |
| MXPA05009715A (es) | 2005-10-18 |
| BRPI0408238A (pt) | 2006-03-01 |
| US20060127405A1 (en) | 2006-06-15 |
| CN1784426A (zh) | 2006-06-07 |
| CN102151334A (zh) | 2011-08-17 |
| DE602004021567D1 (de) | 2009-07-30 |
| RU2345090C2 (ru) | 2009-01-27 |
| KR20050116374A (ko) | 2005-12-12 |
| JP4462964B2 (ja) | 2010-05-12 |
| EP1602669A1 (en) | 2005-12-07 |
| EP1602669A4 (en) | 2006-08-09 |
| US7741447B2 (en) | 2010-06-22 |
| US7361340B2 (en) | 2008-04-22 |
| WO2004081050A1 (ja) | 2004-09-23 |
| US20080146785A1 (en) | 2008-06-19 |
| ES2327408T3 (es) | 2009-10-29 |
| ATE434044T1 (de) | 2009-07-15 |
| AU2004220182A1 (en) | 2004-09-23 |
| CA2518787A1 (en) | 2004-09-23 |
| AU2004220182B2 (en) | 2007-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054631D0 (no) | Antistoff mot tumorspesifikt antigen som mal | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| NO20065227L (no) | Menoklonale antistoff mot hepatocytt vekstfaktor | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| WO2004075865A3 (en) | Selective modulation of tlr-mediated biological activity | |
| CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
| EA200700225A1 (ru) | Аналоги тетрапептида | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| NO20063135L (no) | Farmasoytiske preparater og fremgangsmater for insulinbehandling | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| CY1112953T1 (el) | Χρηση των αντι-cd100 αντισωματων | |
| DE60332163D1 (de) | Zusammensetzung zur hautaufhellung | |
| AR053338A1 (es) | Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos | |
| WO2004080418A3 (en) | Nucleic acid compounds for inhibiting angiogenesis and tumor growth | |
| WO2006009765A3 (en) | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| WO2004033666A3 (en) | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| ATE462699T1 (de) | Substituierte 4,5,6,7-tetrahydro-benzothiazol-2- ylamin-verbindungen | |
| DE60310975D1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| DE50307169D1 (de) | ORALE VAKZINIERUNG MIT DEM TUMOR-ANTIGEN-MIMOTOP Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp | |
| CY1111320T1 (el) | Cripto ειδικα αντισωματα |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |